Pemvidutide (10mg)

What is Pemvidutide?

Pemvidutide, also called ALT-801, is a peptide studied at GLP-1 and glucagon receptors. This catalog lists a 10mg research vial. Receptor activity and liver-related clinical endpoints are different kinds of evidence.

Listed vial contents: 10mg. These are supplied quantities, not administration doses. Current pricing and availability are shown in the strength selector.

What mechanisms are being studied?

Dual agonism allows researchers to examine GLP-1 and glucagon signaling in metabolic models. Liver fat measurements, tissue findings and receptor assays answer different questions and should not be treated as interchangeable.

What are the research questions?

• GLP-1 and glucagon signaling
• Distinguishing liver fat from inflammation and fibrosis endpoints
• Formulation-specific metabolic research

What does the published work describe?

The 2025 IMPACT paper reports 24-week results from a randomized phase 2b trial in adults with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and liver fibrosis. MASH is a liver condition involving fat accumulation and inflammation. The trial studied a defined clinical formulation, not this reagent.

Experimental models in the cited papers

• IMPACT: randomized, double-blind phase 2b human MASH trial

What could future research explore?

Future research can examine how receptor responses relate to distinct liver endpoints. Evidence about tissue inflammation does not automatically establish an effect on fibrosis or predict an outcome in another population.

These are research directions, not established applications of the product sold here.

What are the limits of this evidence?

Clinical findings apply to the tested formulation, trial population and study conditions. They do not establish the identity, safety or effectiveness of this laboratory vial. Research Use Only: this material is not a finished medicine.

Study references

1. Noureddin M, et al. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. Lancet. 2025. PMID 41237796

How should I check lot documentation?

Match the product, strength and lot to an original analysis document. Literature describes experimental findings; it does not verify the contents of this inventory. Generated sample reports illustrate the reporting flow and are not evidence of testing, purity or accreditation.